Gilles W. De Keulenaer

Gilles W. De Keulenaer

Auto-generated profile, based on publicly available information

Gilles W. De Keulenaer

University of Antwerp

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 April 2007 in European Heart Journal
Verified
Journal Article
Open access
PDF file
WPWalter J. Paulus
Walter J. Paulus
CTCarsten Tschöpe
Carsten Tschöpe
JSJohn E. Sanderson
John E. Sanderson
CRCesare Rusconi
Cesare Rusconi
FFFrank A. Flachskampf
Frank A. Flachskampf
DBDirk L. Brutsaert
Dirk L. Brutsaert
Diastolic heart failure (DHF) currently accounts for more than 50% of all heart failure patients. DHF is also referred to as heart failure with normal left ventricular (LV) ejection fraction (HFNEF) to indicate that HFNEF could be a precursor of heart failure with reduced LVEF. Because of improved cardiac imaging and because of widespread clinical use of plasma levels of natriuretic peptides, diagnostic criteria for HFNEF needed to be updated. The diagnosis of HFNEF requires the following conditions to be satisfied: (i) signs or symptoms of heart failure; (ii) normal or mildly abnormal systolic LV function; (iii) evidence of diastolic LV dysfunction. Normal or mildly abnormal systolic LV function implies both an LVEF > 50% and an LV end-diastolic volume index (LVEDVI) 16 mmHg or mean pulmonary capillary wedge pressure >12 mmHg) or non-invasively by tissue Doppler (TD) (E/E′ > 15). If TD yields an E/E′ ratio suggestive of diastolic LV dysfunction (15 > E/E′ > 8), additional non-invasive investigations are required for diagnostic evidence of diastolic LV dysfunction. These can consist of blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, electrocardiographic evidence of atrial fibrillation, or plasma levels of natriuretic peptides. If plasma levels of natriuretic peptides are elevated, diagnostic evidence of diastolic LV dysfunction also requires additional non-invasive investigations such as TD, blood flow Doppler of mitral valve or pulmonary veins, echo measures of LV mass index or left atrial volume index, or electrocardiographic evidence of atrial fibrillation. A similar strategy with focus on a high negative predictive value of successive investigations is proposed for the exclusion of HFNEF in patients with breathlessness and no signs of congestion. The updated strategies for the diagnosis and exclusion of HFNEF are useful not only for individual patient management but also for patient recruitment in future clinical trials exploring therapies for HFNEF.

3 December 2002 in Circulation
Verified
Journal Article
Closed access
PDF file
EWEllen O. Weinberg
Ellen O. Weinberg
MSMasahisa Shimpo
Masahisa Shimpo
GKGilles W. De Keulenaer
Gilles W. De Keulenaer
CMCatherine MacGillivray
Catherine MacGillivray
STShin-Ichi Tominaga
Shin-Ichi Tominaga
RLRichard T. Lee
Richard T. Lee
Background— We identified an interleukin-1 receptor family member, ST2, as a gene markedly induced by mechanical strain in cardiac myocytes and hypothesized that ST2 participates in the acute myocardial response to stress and injury. Methods and Results— ST2 mRNA was induced in cardiac myocytes by mechanical strain (4.7±0.9-fold) and interleukin-1β (2.0±0.2-fold). Promoter analysis revealed that the proximal and not the distal promoter of ST2 is responsible for transcriptional activation in cardiac myocytes by strain and interleukin-1β. In mice subjected to coronary artery ligation, serum ST2 was transiently increased compared with unoperated controls (20.8±4.4 versus 0.8±0.8 ng/mL, P <0.05). Soluble ST2 levels were increased in the serum of human patients (N=69) 1 day after myocardial infarction and correlated positively with creatine kinase ( r =0.41, P <0.001) and negatively with ejection fraction ( P =0.02). Conclusions— These data identify ST2 release in response to myocardial infarction and suggest a role for this innate immune receptor in myocardial injury.

1 April 2016 in JACC: Heart Failure
Verified
Journal Article
Closed access
CFConstantijn Franssen
Constantijn Franssen
SCSophia Chen
Sophia Chen
AUAndreas Unger
Andreas Unger
HKH. Ibrahim Korkmaz
H. Ibrahim Korkmaz
GKGilles W. De Keulenaer
Gilles W. De Keulenaer
NHNazha Hamdani
Nazha Hamdani

1 January 2011 in European Journal of Heart Failure
Verified
Journal Article
Open access
PDF file
TEThomas Eschenhagen
Thomas Eschenhagen
TFThomas Force
Thomas Force
MEMichael S. Ewer
Michael S. Ewer
GKGilles W. de Keulenaer
Gilles W. de Keulenaer
TSThomas M. Suter
Thomas M. Suter
ASAjay M Shah
Ajay M Shah
The reductions in mortality and morbidity being achieved among cancer patients with current therapies represent a major achievement. However, given their mechanisms of action, many anti-cancer agents may have significant potential for cardiovascular side effects, including the induction of heart failure. The magnitude of this problem remains unclear and is not readily apparent from current clinical trials of emerging targeted agents, which generally under-represent older patients and those with significant co-morbidities. The risk of adverse events may also increase when novel agents, which frequently modulate survival pathways, are used in combination with each other or with other conventional cytotoxic chemotherapeutics. The extent to which survival and growth pathways in the tumour cell (which we seek to inhibit) coincide with those in cardiovascular cells (which we seek to preserve) is an open question but one that will become ever more important with the development of new cancer therapies that target intracellular signalling pathways. It remains unclear whether potential cardiovascular problems can be predicted from analyses of such basic signalling mechanisms and what pre-clinical evaluation should be undertaken. The screening of patients, optimization of therapeutic schemes, monitoring of cardiovascular function during treatment, and the management of cardiovascular side effects are likely to become increasingly important in cancer patients. This paper summarizes the deliberations of a cross-disciplinary workshop organized by the Heart Failure Association of the European Society of Cardiology (held in Brussels in May 2009), which brought together clinicians working in cardiology and oncology and those involved in basic, translational, and pharmaceutical science.

21 August 2007 in Circulation
Verified
Journal Article
Open access
PDF file
KLKatrien Lemmens
Katrien Lemmens
KDKris Doggen
Kris Doggen
GKGilles W. De Keulenaer
Gilles W. De Keulenaer
Since the discovery that neuregulin-1 (NRG-1)/ErbB signaling is indispensable in cardiac development, evidence has shown that this system also plays a crucial role in the adult heart. In patients, an inhibitory ErbB2 antibody, trastuzumab, used in the treatment of mammary carcinomas, increases the risk for the development of cardiotoxic cardiomyopathy. Postnatal disruption of NRG-1/ErbB signaling by gene targeting in mice leads to dilated cardiomyopathy. Initially, the search for the mechanisms behind these observations focused mainly on the effects of NRG-1 on cardiomyocyte growth and survival and revealed that NRG-1 has Akt-dependent antiapoptotic effects in cultured cardiomyocytes. In vivo studies, however, did not uniformly reinforce a role for apoptosis in the development of cardiomyopathy induced by impaired NRG-1/ErbB signaling. More recent studies have revealed that NRG-1 is involved in the regulation of cardiac sympathovagal balances by counterbalancing adrenergic stimulation of the adult myocardium and through an obligatory interaction with the muscarinic cholinergic system. NRG-1 is synthesized and released by the endocardial and cardiac microvascular endothelium, dynamically controlled by neurohormonal and biomechanical stimuli. The physiology of the cardiac NRG-1/ErbB system has implications for the treatment of both cancer and heart failure. Clinical studies in breast cancer with novel ErbB inhibitors are currently underway. Novel oncological indications for ErbB inhibition are emerging; cardiovascular side effects need to be carefully monitored. On the other hand, pharmacological activation of ErbB signaling is likely an unrecognized and beneficial effect of currently used drugs in heart failure and a promising therapeutic approach to prevent or reverse myocardial dysfunction.

8 April 2019 in European Heart Journal
Verified
Journal Article
Closed access
PDF file
FTFilippos Triposkiadis
Filippos Triposkiadis
JBJaved Butler
Javed Butler
FAFrancois M Abboud
Francois M Abboud
PAPaul W Armstrong
Paul W Armstrong
SAStamatis Adamopoulos
Stamatis Adamopoulos
GKGilles W De Keulenaer
Gilles W De Keulenaer
Randomized clinical trials initially used heart failure (HF) patients with low left ventricular ejection fraction (LVEF) to select study populations with high risk to enhance statistical power. However, this use of LVEF in clinical trials has led to oversimplification of the scientific view of a complex syndrome. Descriptive terms such as ‘HFrEF’ (HF with reduced LVEF), ‘HFpEF’ (HF with preserved LVEF), and more recently ‘HFmrEF’ (HF with mid-range LVEF), assigned on arbitrary LVEF cut-off points, have gradually arisen as separate diseases, implying distinct pathophysiologies. In this article, based on pathophysiological reasoning, we challenge the paradigm of classifying HF according to LVEF. Instead, we propose that HF is a heterogeneous syndrome in which disease progression is associated with a dynamic evolution of functional and structural changes leading to unique disease trajectories creating a spectrum of phenotypes with overlapping and distinct characteristics. Moreover, we argue that by recognizing the spectral nature of the disease a novel stratification will arise from new technologies and scientific insights that will shape the design of future trials based on deeper understanding beyond the LVEF construct alone.